Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EAG Acquires PTRL West and PTRL Europe

Published: Thursday, April 12, 2012
Last Updated: Thursday, April 12, 2012
Bookmark and Share
EAG adds new division to serve high-end analytical testing needs of the chemical and pesticide industry.

Evans Analytical Group, Inc. (EAG) has announced that it has acquired PTRL West, Inc. (Hercules, CA) and PTRL Europe GmbH (Ulm, Germany).

PTRL West and PTRL Europe will continue to operate under their current names and locations as divisions of EAG. Financial terms of the transaction were not disclosed.

PTRL has created a world-wide business serving the regulatory testing needs of the leading international agrochemical companies.

PTRL provides specialized services in Analytical Chemistry and Residue Analysis, Environmental Fate and Metabolism to assist in the required regulatory testing to bring new pesticides to market and to perform testing required for re-registrations of compounds.

PTRL serves the regulatory requirements of the U.S. EPA, U.S. FDA, EU, REACH, OECD and JMAFF governmental agencies.

The work conducted at the PTRL facilities is in compliance with Good Laboratory Practices (GLP) for the Agrochemical industry and complements our GLP work for the pharmaceutical industry conducted within our EAG Life Sciences Division.

With a continuing commitment to scientific expertise, accuracy of chemical analysis, investment in advanced instrumentation and technologies, and building long-term business partnerships with customers, PTRL has established itself as the premier laboratory for executing challenging analytical work.

For over 20-years, customers from the U.S, Europe and Japan have relied on PTRL as a trusted partner in the complex, regulated process of bringing new pesticides to market.

Harry Davoody, CEO of EAG states "Both PTRL and EAG value our customer relationships first and foremost. The acquisition of PTRL was very compelling to EAG and fits into EAG's overall growth strategy in offering a broader range of high-end analytical services for new and existing customers of EAG. EAG's different divisional strengths complement each other with their best-in-class subject matter expertise which is highly valued by our specialized customers."

Dr. Luis Ruzo, co-founder and Head of PTRL West, affirmed that "PTRL is pleased to become part of an organization as well-regarded as EAG. This merger is very important to PTRL, providing us with additional resources from a solid long-standing company which supports our efforts to continue to grow our labs and our capabilities for our valued customers."

Dr. Thomas Class, co-founder and Head of PTRL Europe, noted "PTRL carefully selected EAG knowing that PTRL and its team will be part of EAG's future growth engine beyond EAG's existing markets. EAG recognized the potential in the agrochemical segment and is very committed to further investing in our business going forward."

Virginia M. Turezyn, SVP of Business Development and Strategy, comments "The agrochemical market sector has been on our radar for some time and we were pleased to have the best-in-class management and team at PTRL to serve as the cornerstone for EAG's entry into this industry."

Neal McCarthy, Managing Director of Fairmount Partners, who assisted PTRL and EAG in this transaction commented "With the acquisition of PTRL, EAG has added the finest agrochemical lab in North America and Europe, and with Dr. Luis Ruzo and Dr. Thomas Class and the other PTRL scientists, EAG adds world class experts in the field of agrochemicals, to its impressive roster of scientific talent."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!